Scinai Immunotherapeutics Ltd. (SCNI) Income Statement
SCNI 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsSCNI revenue and net income
Where SCNI's revenue goes
2025Each bar shows an amount and its share of revenue. SCNI kept −633.6% of revenue as net income.
SCNI profit margins
SCNI growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +99.2% | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | −273.2% | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
SCNI quarterly EPS vs estimates
Scinai Immunotherapeutics beat the analyst EPS estimate in 1 of the last 2 quarters. Next report: November 23, 2026.
SCNI income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $658,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $4.0M | $1.2M | $512,675 | $559,801 | $747,649 | $708,920 | $461,688 | $72,317 | $123,554 | — |
| Gross profit | −$2.7M | −$580,000 | −$512,675 | −$559,801 | −$747,649 | −$708,920 | −$461,688 | −$72,317 | −$123,554 | — |
| Research & development | $2.4M | $5.5M | $5.2M | $5.8M | $2.6M | $14.4M | $19.9M | $19.3M | $5.6M | $2.4M |
| Sales, general & admin | $2.5M | $2.5M | $4.5M | $5.3M | $7.7M | $5.0M | $9.4M | $5.1M | $4.7M | $4.1M |
| Total operating expenses | $4.9M | $8.1M | $9.7M | $11.1M | $10.0M | $19.1M | $22.7M | $20.6M | $6.8M | $3.1M |
| Operating income | −$7.5M | −$8.6M | −$9.7M | −$11.1M | −$10.8M | −$19.8M | −$22.7M | −$20.6M | −$6.8M | −$3.1M |
| Interest income | $20,000 | $100,000 | $123,000 | $5.3M | $3,000 | $1.2M | $4,000 | — | — | — |
| Interest expense | $359,000 | $1.4M | $3.8M | $5.0M | $3.4M | $338,758 | $4.3M | $3.8M | $20,452 | $100 |
| Income before taxes | −$8.3M | $4.8M | −$6.5M | −$5.8M | −$12.4M | −$1.3M | −$31.6M | −$23.5M | −$9.9M | −$2.4M |
| Income taxes | — | — | $0 | $333,515 | $3.5M | −$26.3M | $14.9M | $6.2M | $10.9M | −$55,000 |
| Net income | −$8.3M | $4.8M | −$6.5M | −$5.8M | −$12.4M | −$1.3M | −$31.6M | −$23.5M | −$9.9M | −$2.4M |
| EBITDA | −$6.5M | −$7.0M | −$2.2M | −$5.2M | −$10.3M | −$19.1M | −$22.2M | −$20.5M | −$6.7M | −$2.9M |
| EPS (diluted) | $0.00 | −$42.27 | −$280.25 | −$298.76 | −$1.15 | −$12.04 | −$2900.92 | — | −$549.48 | — |
| Gross margin | −202.3% | −88.1% | — | — | — | — | — | — | — | — |
| Operating margin | −575.3% | −1,312.8% | — | — | — | — | — | — | — | — |
| Net margin | −633.6% | 728.9% | — | — | — | — | — | — | — | — |
| Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $467,898 | $487,674 | $269,000 | $386,500 | $586,000 | $206,000 | $168,000 | $284,000 | $0 | $0 | $0 | $0 |
| Cost of revenue | $1.7M | $1.6M | $960,000 | $1.0M | $358,000 | $373,000 | $417,000 | $448,000 | $157,730 | $84,910 | $144,531 | — |
| Gross profit | −$1.3M | −$1.1M | −$691,000 | −$635,000 | $228,000 | −$167,000 | −$249,000 | −$164,000 | −$157,730 | −$84,910 | −$144,531 | — |
| Research & development | $214,623 | $626,297 | $566,000 | $618,500 | $1.3M | $1.3M | $1.4M | $1.2M | $1.6M | $633,795 | $1.1M | $1.5M |
| Sales, general & admin | $683,000 | $721,000 | — | $755,000 | $501,000 | $759,000 | $764,000 | $519,000 | $484,000 | $1.2M | $968,000 | $1.1M |
| Total operating expenses | $909,351 | $1.3M | $1.2M | $1.2M | $1.8M | $2.5M | $2.2M | −$4.1M | $1.9M | $1.8M | $2.1M | −$9.0M |
| Operating income | −$2.2M | −$2.5M | −$1.9M | −$1.9M | −$1.6M | −$2.3M | −$2.4M | $4.0M | −$1.9M | −$1.9M | −$2.1M | $9.0M |
| Interest income | — | — | — | — | — | $14.7M | $14.8M | — | — | — | $5.2M | — |
| Interest expense | $103,751 | $111,696 | — | $185,500 | $37,000 | $37,000 | $1.9M | $293,924 | $231,000 | $512,495 | $16,836 | $1.2M |
| Income before taxes | −$2.0M | $3.6M | −$2.1M | −$2.1M | −$1.6M | −$2.2M | $10.5M | −$2.3M | −$2.2M | −$2.4M | $3.1M | −$3.8M |
| Income taxes | — | — | — | — | — | — | — | −$1 | $112,724 | $40,188 | $184,586 | — |
| Net income | −$2.0M | $3.6M | −$2.1M | −$2.1M | −$1.6M | −$2.2M | $10.5M | −$2.3M | −$2.2M | −$2.4M | $3.1M | −$3.8M |
| EBITDA | −$1.6M | −$2.0M | −$1.5M | −$1.5M | −$1.2M | −$1.7M | $12.8M | −$1.5M | −$1.8M | −$1.8M | −$2.0M | −$2.4M |
| EPS (diluted) | −$0.74 | $0.94 | −$24.85 | −$2.60 | $4.31 | −$26.35 | $12.39 | −$4.31 | −$24.00 | −$240.00 | $8.00 | −$12.00 |
| Gross margin | −272.2% | −228.6% | −256.9% | −164.3% | 38.9% | −81.1% | −148.2% | −57.7% | — | — | — | — |
| Operating margin | −466.5% | −504.5% | −702.4% | −486.8% | −267.6% | −1,098.5% | −1,440.5% | 1,392.6% | — | — | — | — |
| Net margin | −435.4% | 731.5% | −775.7% | −534.8% | −265.7% | −1,082.5% | 6,223.2% | −817.6% | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in SCNI's financial statements (latest annual report filed April 1, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
SCNI financial results
In fiscal year 2025 (ended December 31, 2025), Scinai Immunotherapeutics reported revenue of $1.3 million, up 99.2% from the year before. It had a net loss of $8.3 million, a net profit margin of −633.6%. Diluted earnings per share came to $0.00.
See the SCNI stock overview for the latest quote and news, or the SCNI chart for price history and technical indicators.
SCNI income statement FAQ
What is Scinai Immunotherapeutics's annual revenue?
Scinai Immunotherapeutics reported total revenue of $1.3 million for fiscal year 2025, which ended on December 31, 2025. That was up 99.2% from $0.7 million the previous year.
Is Scinai Immunotherapeutics profitable?
No. Scinai Immunotherapeutics reported a net loss of $8.3 million in fiscal 2025, a net profit margin of −633.6%; its operating margin was −575.3%.
What is Scinai Immunotherapeutics's gross margin?
Scinai Immunotherapeutics's gross margin was −202.3% in fiscal 2025: for every $100 of revenue, Scinai Immunotherapeutics kept $-202 after the direct cost of its products and services.
How much does Scinai Immunotherapeutics spend on research and development?
Scinai Immunotherapeutics spent $2.4 million on research and development in fiscal 2025, 180.7% of revenue.
What are Scinai Immunotherapeutics's earnings per share?
Scinai Immunotherapeutics earned $-0.00 per diluted share in fiscal 2025, compared with $-42.27 a year earlier.
When will Scinai Immunotherapeutics report its next earnings?
Scinai Immunotherapeutics is expected to report results for the quarter ending September 30, 2026 on November 23, 2026.
When does Scinai Immunotherapeutics's fiscal year end?
Scinai Immunotherapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on April 1, 2026.